SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on February 24, 2011. The filing addresses a regulatory notice received from The NASDAQ Stock Market regarding the company's compliance with listing standards. Note: The request metadata referenced "Riot Platforms, Inc.", but the provided filing text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Listing Status
- NASDAQ Compliance Notice: On February 24, 2011, the Company received notice that NASDAQ granted an additional 180-day extension to regain compliance with the $1.00 minimum bid price rule (Rule 5550(a)(2)).
- Previous Status: The Company was previously notified on August 27, 2010, of non-compliance with the minimum bid price rule, with an initial deadline of February 23, 2011.
- Compliance Requirement: To maintain listing, the closing bid price of the common stock must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to August 22, 2011.
- Delisting Risk: Failure to meet the requirement by the deadline will result in written notification of delisting from the NASDAQ Capital Market. The Company retains the right to appeal such a determination to a NASDAQ Listings Qualifications Panel.
Outlook, Risks, and Management Commentary
The filing contains forward-looking statements regarding the Company's ability to regain compliance. Management highlights the risk that the Company may not achieve the required bid price by August 22, 2011. The Company states it does not intend to update these statements unless required by law. No specific operational guidance or financial outlook is provided in this document.
Investor Verification Checklist
- Verify the current trading price of AspenBio Pharma, Inc. common stock to assess proximity to the $1.00 threshold.
- Review the Company's most recent Forms 10-K and 10-Q for detailed financial health and liquidity status, as this 8-K does not contain them.
- Monitor the stock's closing bid price over the next 10 consecutive trading days to track progress toward the August 22, 2011 deadline.
- Check for any subsequent press releases or filings regarding a potential appeal to the NASDAQ Listings Qualifications Panel if the deadline is missed.